Future Directions and Unmet Needs in Relapsed/Refractory MCL
A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
Read More
Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia
February 16th 2024Dr. Shah and faculty provide updates on emerging therapies, which exhibit promise for the treatment of relapsed or refractory acute lymphoblastic leukemia such as tisagenlecleucel and Obe-cel; obecabtagene autoleucel, preliminary outcomes of which were presented in the FELIX study at the 65th ASH Annual Meeting.
Read More
Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL
February 16th 2024Dr. Shah and colleagues dissect the social determinants of health, including limited personal resources, frailty, distance to treatment facilities, therapeutic compliance, and other considerations that impact effective treatment sequencing for patients with relapsed or refractory ALL, including access to care and CAR-T cell availability.
Read More
Sequencing Therapies in the Third-Line and Beyond Setting for MCL
A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.
Read More
Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy
February 9th 2024Dr. Park and co-panelists review the patient and disease characteristics, including patient age, high pre-apheresis disease burden, and bridging response to inotuzumab or blinatumomab among other variables that might best support consideration of post-CART19 maintenance therapy.
Read More
ASH 2023 Updates on Frontline Therapies in MCL
A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.
Read More
Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion
February 2nd 2024Dr. Roloff and colleagues offer expert opinion on optimizing treatment sequences for patients with relapsed or refractory ALL who have received two or more prior lines of therapy and the disease and patient factors that inform their treatment plans.
Read More
Unmet Needs in Treating Relapsed/Refractory FL
Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.
Read More
Objectives, Clinical Endpoints, and Safety Profile of the Phase 2 ZUMA-3 Clinical Trial
January 26th 2024Dr. Bijal and colleagues discuss the objectives, clinical outcomes, and safety profile of the Phase 2 ZUMA 3 clinical trial, which evaluated treatment of adult patients with relapsed or refractory, B-precursor, acute lymphoblastic leukemia with the anti-CD-19/anti-CD20 bispecific CAR-T cell therapy, KTE-X19 (brexucabtagene autoleucel).
Read More
Overview of the Current State of CART19 Therapy for Adult Patients With R/R ALL
January 26th 2024Drs. Roloff, Park, and Shah provide a brief overview of the current, CAR-T cell therapeutic landscape for relapsed or refractory acute lymphoblastic leukemia in adults with a particular focus on those who have completed two or more lines of prior therapy.
Read More
Objectives of the 2023 ASH Insights Program on CAR-T Cell Therapy for Adult B Cell ALL
January 26th 2024Faculty review the objectives of the 2023 ASH Insights Program on the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic Leukemia.
Read More
Sequencing Immunotherapy in the Third-line and Beyond Setting for FL
Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.
Read More
Choosing CAR T-cells as Third-line and Beyond Therapy for FL
Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.
Read More
Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL
A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.
Read More
Zanubrutinib as Third-Line and Beyond Therapy for FL
Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.
Read More
Tazemetostat as Third-line and Beyond Therapy for FL
Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.
Read More
Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL
Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.
Read More
CAR T-cells as Third-line and Beyond Therapy for FL
Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.
Read More
ASH 2023 Updates on Frontline Therapies in FL
A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.
Read More